$ZTS

Michael Burry adjusted his portfolio, identifying Deckers Outdoor (DECK), lululemon (LULU), Fannie Mae (FNMA), Freddie Mac (FMCC), Fiserv (FISV), Sprouts Farmers Market (SFM), Zoetis (ZTS), and MetLife (MET) as vulnerable to tax-loss selling. He swapped DECK for LULU, FMCC for FNMA, and shifted SFM and ZTS into long-term call options. Burry also added put options on MET, citing risks in private credit and equity valuations.

Zoetis Inc. reported a study showing Simparica Trio outperformed NexGard Plus in protecting dogs against ML-resistant heartworm. The peer-reviewed lab study, funded by Zoetis, found Simparica Trio provided better protection after six monthly doses. This supports Zoetis' strategy to differentiate its product amid rising concerns over resistant heartworm.

Michael Burry identified six stocks as potential tax-loss sale candidates, including LULU, DECK, FNMA, FMCC, FISV, SFM, and ZTS. He swapped LULU for DECK, exited FNMA for FMCC, and adjusted positions in FISV, SFM, and ZTS. Burry added put options on MET due to concerns about private credit and equity valuations.

Corcept (CORT) beat estimates and raised guidance, with its stock up 23.2%. Zoetis (ZTS) reported flat revenue, missing expectations, and its stock fell 4.2%. Collegium Pharmaceutical (COLL) saw a 6.3% revenue increase but missed guidance, with its stock down 36.7%. Pfizer (PFE) reported a 2.6% revenue increase, beating expectations, and its stock rose 14.8%.

Michael Burry, known for 'The Big Short,' has invested in Ero Copper (ERO), QXO (QXO), Temple & Webster, Sprouts Farmers Market (SFM), and Zoetis (ZTS), avoiding the AI trend. He sees value in copper due to supply-demand imbalances and expects Ero's margins to expand. QXO's preferred shares offer a 7.4% yield. Temple & Webster's revenue grew 11% in FY2026, while SFM and ZTS have declined significantly.

Michael Burry sold his entire position in Flutter Entertainment (FLUT) and reinvested most of the proceeds into Lululemon Athletica (LULU) at under $100, citing compressed valuation. He also increased his stake in Zoetis (ZTS), calling it 'very cheap.' FLUT, LULU, and ZTS were trading at -1.5%, +0.09%, and +0.3% respectively in after-hours trading.

Pfizer (PFE) raised its 2026 revenue guidance by $500M, while Zoetis (ZTS) cut its outlook, expecting a 1-3% decline. Pfizer's growth is driven by drugs like Eliquis and Padcev, while Zoetis faces market share pressures. Pfizer aims for high single-digit revenue CAGR from 2028-2033, with $9.7B in expected savings. Zoetis is investing in dermatology and adjusting prices to combat competition.

Zoetis appointed Jay Saccaro as Executive Vice President, CFO, and COO, combining finance and operations. Saccaro previously served as CFO at GE HealthCare and Baxter. GE HealthCare named William Grogan as CFO, effective September 14, succeeding Saccaro.

Impax US Sustainable Economy Fund reported Q2 2026 performance, with shares in Zoetis (ZTS) dropping due to earnings revision. Zoetis, an animal health company, faced sales headwinds for its Librela product and delayed next-gen launches. The stock closed at $75.81 on September 4, 2026, down 50.04% year-over-year. The fund noted Zoetis' sustainability profile but sees greater upside in AI stocks.

Zoetis (ZTS) has underperformed the S&P 500, with United Therapeutics (UTHR) showing better performance. Analysts rate ZTS as a 'Moderate Buy' with a mean price target of $97.69, suggesting 28.3% upside.